Realizing Biotech Aspirations
With Saudi Arabia striving to position itself as a regional leader in biopharmaceutical R&D by 2030 and to cement itself as a global hub before 2040, there has been a…
With Saudi Arabia striving to position itself as a regional leader in biopharmaceutical R&D by 2030 and to cement itself as a global hub before 2040, there has been a…
Saudi Arabia has long represented an alluring marketplace for the global MedTech industry. Not only does the Kingdom constitute the largest spender on healthcare across the Middle East and North…
Eye health is vital to everyday life, yet it remains heavily underfunded compared to fields like cancer or diabetes. While global spending on oncology is set to reach USD 440…
With increased average disposable income in Saudi Arabia eliciting more sedentary lifestyles and less healthy dietary choices, more than 68 percent of all mortality in the Kingdom is nowadays attributed…
When it was first initiated back in 2016, in the wake of the launch of Vision 2030, few industry insiders could have anticipated just quite how radical Saudi Arabia’s Health…
Saudi Arabia’s pharmaceuticals market grew an impressive 9.1 percent in 2024 underscoring its position as the regional heavyweight, and projecting a sales value of around USD 11.6 billion, which constitutes…
Radioligand therapy (RLT), a specialized type of radiopharmaceutical therapy (RPT) that targets markers on tumor cells, is becoming a cancer treatment game changer. With a first FDA approval for Novartis’…
Diego Salas from the Latin American Federation of the Pharmaceutical Industry (FIFARMA) and Carlos Felipe Escobar Roa from the Instituto de Prospectiva e Innovacion en Salud (INNOS), writing in the…
In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
2023 may have been a breakthrough year for cell and gene therapies with the FDA approving a record of seven novel treatments, but 2024 did not fall behind in the…
Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare…
See our Cookie Privacy Policy Here
